Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coxiella burnetii antigens are the molecular components of the obligate intracellular Gram-negative bacterium responsible for Q fever, a zoonotic disease. These antigens primarily include surface-exposed proteins and lipopolysaccharides (LPS) that exhibit significant phase variation; Phase I antigens possess a full-length, smooth LPS that masks surface proteins from the host immune system and is highly infectious, while Phase II antigens have a truncated, rough LPS and are typically less virulent (Source: CDC, NIH). These antigens are critical for the pathogen's ability to invade host macrophages and survive within the harsh, acidic environment of the phagolysosome (Source: PubMed, PMC4481352). In a therapeutic context, these antigens serve as the basis for vaccines, such as the whole-cell Q-Vax, which aim to elicit protective T-cell mediated immunity and antibody production (Source: StatPearls). However, the use of these antigens in vaccines is complicated by the risk of severe inflammatory reactions in individuals with prior exposure to the bacterium, necessitating rigorous pre-screening protocols (Source: Australian Immunisation Handbook).
Induction of active immunity through the stimulation of humoral (B-cell) and cellular (T-cell) immune responses against the Coxiella burnetii bacterium.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coxiella burnetii antigens (C. burnetii antigens).